Teriparatide transdermal - Corium International

Drug Profile

Teriparatide transdermal - Corium International

Alternative Names: hPTH(1-34) - Corium International; Human PTH(1-34) - Corium International; MicroCor PTH; Parathyroid hormone (1-34) - Corium International; Parathyroid hormone transdermal - Corium International; PTH (1-34) - Corium International

Latest Information Update: 06 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Corium International
  • Class Osteoporosis therapies; Peptide hormones; Skin disorder therapies
  • Mechanism of Action Parathyroid hormone receptor type 1 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Osteoporosis

Most Recent Events

  • 06 Sep 2017 Teriparatide is still undergoing phase-II clinical trials in Osteoporosis (In adults, In elderly) in Australia (Transdermal)
  • 28 Jul 2015 Interim pharmacokinetics, pharmacodynamics and adverse events data from a phase IIa trial in Osteoporosis (In adults, In elderly) released by Corium International
  • 01 Feb 2015 Phase-II clinical trials in Osteoporosis (In adults, In elderly) in Australia (Transdermal) (ACTRN12615000195550)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top